Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

PaperCitations, authors & open-access status

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,360 citations, 2008 year and closed oa status.

1,360
Citations
2008
Year
closed
OA Status

Related on ScholarIQ

Philippe Szapary
Author
The Lancet
Journal
Psoriasis: Treatment and Pathogenesis
Topic
Psoriasis: Treatment and Pathogenesis
Topic
Dermatology and Skin Diseases
Topic
Asthma and respiratory diseases
Topic
470M+ articles · free account